Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $2.00 price target on shares of Aptose Biosciences in a research report on Tuesday, December 10th.

Aptose Biosciences Trading Up 63.9 %

Shares of APTO stock opened at $0.28 on Monday. The stock has a market cap of $16.79 million, a P/E ratio of -0.09 and a beta of 1.06. Aptose Biosciences has a 1 year low of $0.13 and a 1 year high of $2.68. The stock has a 50 day simple moving average of $0.30 and a 200 day simple moving average of $0.47.

Hedge Funds Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent reporting period. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.